Canada markets closed

Aprea Therapeutics, Inc. (APRE)

NasdaqGS - NasdaqGS Real Time Price. Currency in USD
Add to watchlist
0.9500-0.0386 (-3.90%)
At close: 04:00PM EDT
0.9800 +0.03 (+3.16%)
After hours: 05:18PM EDT
Full screen
Loading interactive chart...
  • GlobeNewswire

    Aprea Therapeutics Reports Second Quarter 2022 Financial Results and Provides Update on Business Operations

    BOSTON, Aug. 11, 2022 (GLOBE NEWSWIRE) -- Aprea Therapeutics, Inc. (Nasdaq: APRE), a biopharmaceutical company focused on developing and commercializing novel synthetic lethality-based cancer therapeutics targeting DNA damage response (DDR) pathways today reported financial results for the three and six months ended June 30, 2022 and provided a business update. “This is an exciting time for Aprea as we advance our ATR program into clinical development this year, continue to progress our WEE1 pro

  • GlobeNewswire

    Aprea Therapeutics to Participate in the 2022 Wedbush PacGrow Healthcare Conference

    BOSTON, Mass., Aug. 02, 2022 (GLOBE NEWSWIRE) -- Aprea Therapeutics, Inc. (Nasdaq: APRE), a biopharmaceutical company focused on developing and commercializing novel cancer therapeutics targeting DNA damage response pathways, today announced that Oren Gilad Ph.D, President and Chief Executive Officer, will participate in a panel discussion on synthetic lethality at the 2022 Wedbush PacGrow Healthcare Conference on Tuesday, August 9, 2022 at 12:35 p.m. ET. The panel discussion will be hosted by R

  • GlobeNewswire

    Aprea Therapeutics Announces Acquisition of Atrin Pharmaceuticals Inc. and Reports First Quarter 2022 Financial Results

    BOSTON, May 16, 2022 (GLOBE NEWSWIRE) -- Aprea Therapeutics, Inc. (Nasdaq: APRE), a biopharmaceutical company focused on developing and commercializing novel cancer therapeutics targeting DNA damage response pathways today announced that it has acquired Atrin Pharmaceuticals Inc. (“Atrin”) and reported financial results for the three months ended March 31, 2022. Business Operations Update: On May 16, 2022 Aprea completed the acquisition of Atrin, a privately held biotechnology company focused on